

Munitta Muthana

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8377039/publications.pdf>

Version: 2024-02-01

26
papers

2,443
citations

623734

14
h-index

610901

24
g-index

27
all docs

27
docs citations

27
times ranked

4716
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of myeloid cells in the promotion of tumour angiogenesis. <i>Nature Reviews Cancer</i> , 2008, 8, 618-631.	28.4	1,404
2	Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. <i>Cancer Research</i> , 2015, 75, 3479-3491.	0.9	375
3	Directing cell therapy to anatomic target sites in vivo with magnetic resonance targeting. <i>Nature Communications</i> , 2015, 6, 8009.	12.8	126
4	Use of Macrophages to Target Therapeutic Adenovirus to Human Prostate Tumors. <i>Cancer Research</i> , 2011, 71, 1805-1815.	0.9	111
5	Macrophage Delivery of an Oncolytic Virus Abolishes Tumor Regrowth and Metastasis after Chemotherapy or Irradiation. <i>Cancer Research</i> , 2013, 73, 490-495.	0.9	76
6	An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 9309-9333.	6.4	47
7	C5orf30 is a negative regulator of tissue damage in rheumatoid arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 11618-11623.	7.1	26
8	Tumour infiltrating host cells and their significance for hyperthermia. <i>International Journal of Hyperthermia</i> , 2010, 26, 247-255.	2.5	25
9	Oncolytic herpesvirus therapy for mesothelioma – A phase I/IIa trial of intrapleural administration of HSV1716. <i>Lung Cancer</i> , 2020, 150, 145-151.	2.0	25
10	Designer nanocarriers for navigating the systemic delivery of oncolytic viruses. <i>Nanomedicine</i> , 2020, 15, 93-110.	3.3	24
11	Development of a New Hyaluronic Acid Based Redox-Responsive Nanohydrogel for the Encapsulation of Oncolytic Viruses for Cancer Immunotherapy. <i>Nanomaterials</i> , 2021, 11, 144.	4.1	23
12	Understanding Immune Responses to Viruses – Do Underlying Th1/Th2 Cell Biases Predict Outcome?. <i>Viruses</i> , 2022, 14, 1493.	3.3	20
13	Macrophages and Neutrophils: Regulation of the Inflammatory Microenvironment in Autoimmunity and Cancer. <i>Mediators of Inflammation</i> , 2016, 2016, 1-3.	3.0	18
14	Oestrogen and zoledronic acid driven changes to the bone and immune environments: Potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions. <i>Journal of Bone Oncology</i> , 2020, 25, 100317.	2.4	18
15	Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 589-601.	4.1	16
16	Identification of a rat bone marrow-derived dendritic cell population which secretes both IL-10 and IL-12: Evidence against a reciprocal relationship between IL-10 and IL-12 secretion. <i>Immunobiology</i> , 2006, 211, 391-402.	1.9	13
17	Oncolytic Virotherapy Treatment of Breast Cancer: Barriers and Recent Advances. <i>Viruses</i> , 2021, 13, 1128.	3.3	13
18	The Autoimmune Susceptibility Gene C5orf30 Regulates Macrophage-Mediated Resolution of Inflammation. <i>Journal of Immunology</i> , 2019, 202, 1069-1078.	0.8	12

#	ARTICLE	IF	CITATIONS
19	Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. , 2021, 9, e001803.		12
20	Nanoparticles: Properties and Applications in Cancer Immunotherapy. Current Pharmaceutical Design, 2019, 25, 1962-1979.	1.9	12
21	Nanobugs as Drugs: Bacterial Derived Nanomagnets Enhance Tumor Targeting and Oncolytic Activity of HSV-1 Virus. Small, 2022, 18, e2104763.	10.0	12
22	Magnetosomes and Magnetosome Mimics: Preparation, Cancer Cell Uptake and Functionalization for Future Cancer Therapies. Pharmaceutics, 2021, 13, 367.	4.5	11
23	Targeting circulating monocytes with CCL2-loaded liposomes armed with an oncolytic adenovirus. Nanomedicine: Nanotechnology, Biology, and Medicine, 2022, 40, 102506.	3.3	11
24	Specific Targeting of PEGylated Liposomal Doxorubicin (Doxil®) to Tumour Cells Using a Novel TIMP3 Peptide. Molecules, 2021, 26, 100.	3.8	8
25	Oestradiol Contributes to Differential Antitumour Effects of Adjuvant Zoledronic Acid Observed Between Pre- and Post-Menopausal Women. Frontiers in Endocrinology, 2021, 12, 749428.	3.5	3
26	Inconsistencies in Modeling the Efficacy of the Oncolytic Virus HSV1716 Reveal Potential Predictive Biomarkers for Tolerability. Frontiers in Molecular Biosciences, 0, 9, .	3.5	2